Fesoterodine Medical Valley
Extended-release tablet for overactive bladder (OAB)
Quick Facts About Fesoterodine Medical Valley
Key Takeaways About Fesoterodine Medical Valley
- Used for overactive bladder: Fesoterodine treats urgency, urge incontinence, and frequent urination in adults by relaxing the bladder muscle
- Start with 4 mg, may increase to 8 mg: The recommended starting dose is 4 mg once daily, with the option to increase based on individual response and tolerability
- Dry mouth is the most common side effect: Occurring in more than 1 in 10 users, dry mouth is usually mild to moderate and can increase dental caries risk
- Multiple contraindications exist: Do not take if you have urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, or severe liver problems
- Drug interactions require careful management: Strong CYP3A4 inhibitors can significantly increase fesoterodine levels, requiring dose adjustment or avoidance in patients with kidney or liver impairment
What Is Fesoterodine Medical Valley and What Is It Used For?
Fesoterodine Medical Valley is an antimuscarinic medication containing fesoterodine fumarate as its active ingredient. It is used in adults to treat the symptoms of overactive bladder (OAB), including urinary urgency, urge incontinence, and increased urinary frequency.
Fesoterodine Medical Valley belongs to a class of medications called antimuscarinics (also known as anticholinergics). These medications work by blocking specific receptors called muscarinic receptors in the smooth muscle of the urinary bladder. By inhibiting these receptors, fesoterodine reduces involuntary contractions of the detrusor muscle, which is the muscle that contracts to empty the bladder. This mechanism helps to decrease the urgency and frequency of urination, as well as episodes of urge incontinence.
Overactive bladder is a common condition that affects millions of people worldwide. It is characterized by a sudden, compelling desire to urinate that is difficult to defer (urgency), often accompanied by increased daytime and nighttime urinary frequency. In some cases, urgency is associated with involuntary leakage of urine, known as urge incontinence. OAB can significantly impair quality of life, affecting sleep, work productivity, and social activities.
After oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its primary active metabolite, 5-hydroxymethyl tolterodine (5-HMT). This active metabolite is responsible for the therapeutic effect of the drug. The extended-release formulation is designed to provide consistent drug levels throughout the day, allowing for once-daily dosing and improved adherence to treatment.
Overactive bladder is a clinical diagnosis based on symptoms. Fesoterodine treats the symptoms but does not cure the underlying condition. Behavioral therapies such as bladder training, pelvic floor exercises, and fluid management are often recommended alongside pharmacological treatment for optimal outcomes.
How does fesoterodine work in the body?
Once ingested, fesoterodine fumarate acts as a prodrug. It is quickly converted in the body to its active metabolite, 5-hydroxymethyl tolterodine (5-HMT), through the action of nonspecific esterases in the blood. This conversion does not depend on liver enzymes (specifically CYP enzymes) for the initial step, which means the activation process is reliable across different patient populations.
The active metabolite 5-HMT is a competitive antagonist at muscarinic M2 and M3 receptors. The M3 receptors are primarily responsible for bladder smooth muscle contraction, while M2 receptors play a modulatory role. By blocking these receptors, fesoterodine reduces the force and frequency of involuntary detrusor contractions during the bladder filling phase, thereby increasing the bladder's functional capacity and decreasing episodes of urgency and incontinence.
Clinical trials have demonstrated that fesoterodine significantly reduces the number of urgency episodes, incontinence episodes, and micturitions (urinations) per 24 hours compared to placebo. The 8 mg dose has been shown to provide additional benefit over the 4 mg dose in some patients, particularly those with more severe symptoms.
What Should You Know Before Taking Fesoterodine Medical Valley?
Before starting Fesoterodine Medical Valley, you must inform your doctor about all your medical conditions, particularly urinary retention, glaucoma, myasthenia gravis, liver or kidney problems, and heart conditions. Several absolute contraindications exist that prevent safe use of this medication.
Contraindications
Fesoterodine Medical Valley must not be used in the following situations. If any of these apply to you, inform your doctor immediately, as an alternative treatment will need to be considered:
- Allergy to fesoterodine or fructose: If you are allergic to the active substance, fructose, or any other ingredient in the tablet
- Urinary retention: If you cannot fully empty your bladder, fesoterodine could worsen this condition by further relaxing the bladder muscle
- Gastric retention: If your stomach empties abnormally slowly, antimuscarinic medications can further delay gastric motility
- Uncontrolled narrow-angle glaucoma: Antimuscarinics can increase intraocular pressure, potentially worsening this eye condition
- Myasthenia gravis: This neuromuscular condition can be exacerbated by anticholinergic medications
- Severe ulcerative colitis: Antimuscarinic drugs may suppress intestinal motility, potentially leading to toxic megacolon
- Toxic megacolon: A life-threatening dilation of the colon that can be worsened by reduced gut motility
- Severe hepatic impairment: The metabolism of fesoterodine may be significantly altered in severe liver disease
Patients with kidney problems or moderate-to-severe liver problems who are also taking strong CYP3A4 inhibitors (such as ketoconazole, itraconazole, ritonavir, atazanavir, indinavir, saquinavir, nelfinavir, clarithromycin, telithromycin, or nefazodone) must not use fesoterodine, as dangerous drug levels may accumulate.
Warnings and Precautions
Talk to your doctor before taking Fesoterodine Medical Valley if any of the following conditions apply to you, as your treatment may require special monitoring or dose adjustment:
- Bladder outflow obstruction: Difficulty fully emptying the bladder (e.g., due to enlarged prostate) increases the risk of urinary retention with antimuscarinic medications
- Gastrointestinal obstructive disorders: Reduced bowel motility or severe constipation can be worsened by anticholinergic effects
- Controlled narrow-angle glaucoma: Even when treated, regular monitoring of intraocular pressure is recommended
- Significant kidney or liver disease: Dose adjustment may be necessary, and your doctor may need to monitor you more closely
- Autonomic neuropathy: This condition affecting the autonomic nervous system may alter blood pressure regulation, bowel function, or sexual function
- Hiatal hernia or gastroesophageal reflux: Anticholinergic medications can worsen acid reflux symptoms
- Urinary tract infection: Your doctor may need to prescribe antibiotics before or during treatment
Heart-related precautions
Discuss with your doctor if you have any of the following cardiovascular conditions, as antimuscarinic medications can potentially affect heart rhythm:
- QT prolongation: An abnormality visible on an electrocardiogram (ECG) that increases the risk of dangerous heart rhythms
- Bradycardia: An abnormally slow heart rate may be further affected by antimuscarinic drugs
- Myocardial ischemia: Reduced blood flow to the heart muscle requires careful monitoring during anticholinergic therapy
- Heart failure or arrhythmias: These conditions can be complicated by changes in autonomic tone caused by antimuscarinics
- Hypokalemia: Low potassium levels in the blood can increase the risk of cardiac arrhythmias when combined with medications that affect the QT interval
Pregnancy and Breastfeeding
Fesoterodine Medical Valley should not be used during pregnancy because the effects of fesoterodine on the developing fetus have not been adequately studied. There are no well-controlled clinical trials in pregnant women, and the potential risks to the unborn child are unknown. Women of childbearing potential should use effective contraception during treatment.
It is not known whether fesoterodine or its active metabolite passes into breast milk. As a precautionary measure, breastfeeding should be discontinued during treatment with Fesoterodine Medical Valley. If you are pregnant, planning to become pregnant, or breastfeeding, consult your healthcare provider before starting this medication.
Children and adolescents
Fesoterodine Medical Valley is not approved for use in children and adolescents under 18 years of age. The safety and efficacy of fesoterodine in the pediatric population have not been established, and its use in this age group is not recommended.
Driving and operating machinery
Fesoterodine Medical Valley may cause blurred vision, dizziness, and drowsiness. If you experience any of these effects, do not drive a vehicle or operate machinery until these symptoms have resolved. You are responsible for assessing your own fitness to drive or perform tasks requiring alertness.
Excipient warnings
Fesoterodine Medical Valley tablets contain both lactose and fructose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medication. Each extended-release tablet contains 72 mg of fructose. Fructose may be harmful to teeth.
How Does Fesoterodine Medical Valley Interact with Other Drugs?
Fesoterodine can interact with multiple drug classes including strong CYP3A4 inhibitors (which increase its blood levels), CYP3A4 inducers (which decrease its effectiveness), and other anticholinergic medications (which may increase side effects). Always inform your doctor about all medications you are taking.
Drug interactions with fesoterodine are clinically significant and can lead to either increased side effects or reduced therapeutic efficacy. The active metabolite of fesoterodine, 5-HMT, is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and, to a lesser extent, by CYP2D6. Medications that inhibit or induce these enzymes can significantly alter fesoterodine blood levels.
Major interactions - drugs that increase fesoterodine levels
Strong CYP3A4 inhibitors can substantially increase blood levels of fesoterodine's active metabolite, potentially leading to increased side effects. In patients with kidney or moderate-to-severe liver impairment, concurrent use with the following medications is contraindicated:
| Drug | Category | Effect on Fesoterodine | Clinical Action |
|---|---|---|---|
| Ketoconazole, Itraconazole | Antifungal | Significantly increases blood levels | Contraindicated with renal/hepatic impairment; limit dose to 4 mg in others |
| Ritonavir, Atazanavir, Saquinavir, Indinavir, Nelfinavir | HIV Antivirals | Significantly increases blood levels | Contraindicated with renal/hepatic impairment; limit dose to 4 mg in others |
| Clarithromycin, Telithromycin | Antibiotics | Significantly increases blood levels | Contraindicated with renal/hepatic impairment; limit dose to 4 mg in others |
| Nefazodone | Antidepressant | Significantly increases blood levels | Contraindicated with renal/hepatic impairment; limit dose to 4 mg in others |
| Fluoxetine, Paroxetine | SSRI Antidepressants | Moderately increases blood levels (CYP2D6 inhibition) | Monitor for increased side effects; dose adjustment may be needed |
| Bupropion | Antidepressant / Smoking cessation | Moderately increases blood levels | Monitor for increased side effects |
| Quinidine | Antiarrhythmic | Moderately increases blood levels | Monitor for increased side effects |
| Cinacalcet | Calcimimetic | Moderately increases blood levels | Monitor for increased side effects |
Drugs that decrease fesoterodine effectiveness
CYP3A4 inducers can accelerate the metabolism of fesoterodine's active metabolite, leading to reduced blood levels and potentially decreased therapeutic efficacy. If you are taking any of the following medications, your doctor may need to consider alternative treatments or adjust the dosing strategy:
- Rifampicin: A potent CYP3A4 inducer used to treat tuberculosis and other bacterial infections
- St. John's Wort (Hypericum perforatum): An herbal supplement used for depression that is a well-known CYP3A4 inducer
- Carbamazepine: An anticonvulsant used to treat epilepsy and neuropathic pain
- Phenytoin: An anticonvulsant used to treat epilepsy
- Phenobarbital: A barbiturate used as an anticonvulsant
Additive anticholinergic effects
Taking fesoterodine with other medications that have anticholinergic properties can increase the risk and severity of side effects such as dry mouth, constipation, urinary retention, and drowsiness. Inform your doctor if you are taking any of the following:
- Amantadine: Used to treat Parkinson's disease
- Metoclopramide: Used for gastrointestinal motility and nausea
- Tricyclic antidepressants and certain antipsychotic medications
- Methadone: Used for pain management and opioid use disorder
What Is the Correct Dosage of Fesoterodine Medical Valley?
The recommended starting dose is 4 mg once daily. Based on individual response and tolerability, your doctor may increase the dose to 8 mg once daily. The tablet must be swallowed whole with water and should not be chewed, split, or crushed.
Always take Fesoterodine Medical Valley exactly as prescribed by your doctor. The dosing regimen is straightforward, and maintaining consistency in the time of administration can help you remember to take your medication and maintain steady drug levels throughout the day.
Adults
Standard adult dosing
- Starting dose: 4 mg once daily
- Maximum dose: 8 mg once daily (based on individual response)
- Administration: Swallow whole with water; do not chew, split, or crush
- Timing: Can be taken at any time of day, with or without food
- Consistency: Take at the same time each day for best adherence
Your doctor will typically start you on the 4 mg dose and evaluate your response after a suitable period. If the 4 mg dose provides insufficient symptom control and you are tolerating the medication well, your doctor may increase the dose to 8 mg once daily. The decision to increase the dose should be based on a careful assessment of both efficacy and side effects.
Special populations
| Patient Group | Recommended Dose | Notes |
|---|---|---|
| Healthy adults | 4 mg, may increase to 8 mg | Standard dosing regimen |
| Elderly patients | 4 mg, may increase to 8 mg | No dose adjustment required; monitor for side effects |
| Mild hepatic impairment | 4 mg, may increase to 8 mg | No dose adjustment required |
| Moderate hepatic impairment | Maximum 4 mg | Do not exceed 4 mg; monitor closely |
| Severe hepatic impairment | Contraindicated | Do not use |
| Renal impairment | Maximum 4 mg (if severe) | Dose restriction with severe renal impairment |
| Taking strong CYP3A4 inhibitors | Maximum 4 mg | Contraindicated if combined with renal/hepatic impairment |
| Children (<18 years) | Not recommended | Safety and efficacy not established |
Missed Dose
If you forget to take a dose of Fesoterodine Medical Valley, take it as soon as you remember. However, do not take more than one tablet per day. If it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Never take a double dose to make up for a forgotten tablet.
Overdose
If you have taken more Fesoterodine Medical Valley than prescribed, or if a child has accidentally ingested the medication, contact your doctor, hospital emergency department, or poison control center immediately. Show the medication packaging to healthcare professionals. Symptoms of overdose may include severe dry mouth, difficulty urinating, constipation, blurred vision, rapid heartbeat, confusion, and drowsiness. Treatment is symptomatic and supportive.
Do not stop taking Fesoterodine Medical Valley without consulting your doctor, as symptoms of overactive bladder may return or worsen if the medication is discontinued abruptly. Your doctor can advise on the best approach if discontinuation is needed.
What Are the Side Effects of Fesoterodine Medical Valley?
Like all medicines, fesoterodine can cause side effects, though not everyone experiences them. The most common side effect is dry mouth, affecting more than 1 in 10 users. Serious allergic reactions including angioedema are rare but require immediate medical attention.
Side effects of fesoterodine are generally related to its anticholinergic mechanism of action. Most adverse effects are mild to moderate in severity and may diminish as your body adjusts to the medication. The likelihood and severity of side effects tend to be dose-dependent, with higher rates observed at the 8 mg dose compared to the 4 mg dose.
In rare cases, severe allergic reactions including angioedema (swelling of the face, mouth, or throat) may occur. Stop taking Fesoterodine Medical Valley and contact your doctor or emergency services immediately if you experience swelling of the face, lips, tongue, or throat, as this can be life-threatening.
Very Common
- Dry mouth (usually mild to moderate; may increase risk of dental caries — brush teeth regularly twice daily)
Common
- Dry eyes
- Constipation
- Indigestion (dyspepsia)
- Difficulty or pain when urinating (dysuria)
- Dizziness
- Headache
- Abdominal pain
- Diarrhea
- Nausea
- Difficulty sleeping (insomnia)
- Dry throat
Uncommon
- Urinary tract infection
- Drowsiness (somnolence)
- Taste disturbances (dysgeusia)
- Vertigo
- Rash, dry skin, itching
- Stomach discomfort, flatulence
- Difficulty emptying the bladder completely (urinary retention)
- Difficulty starting urination
- Fatigue
- Increased heart rate (tachycardia), palpitations
- Liver problems
- Cough, nasal dryness, sore throat
- Acid reflux (gastroesophageal reflux)
- Blurred vision
Rare
- Hives (urticaria)
- Confusion
- Decreased sensation around the mouth (oral hypoesthesia)
Managing common side effects
Dry mouth, the most frequently reported side effect, can be managed with several strategies. Sugar-free gum or lozenges can stimulate saliva production. Frequent sips of water throughout the day help maintain oral moisture. Good oral hygiene is particularly important because reduced saliva increases the risk of dental caries. If dry mouth becomes problematic, your doctor may consider dose reduction or switching to an alternative medication.
Constipation can often be managed with increased dietary fiber, adequate fluid intake, and regular physical activity. If constipation becomes severe or persistent, contact your doctor, as medication adjustments may be needed. Avoid using over-the-counter laxatives without medical advice.
How Should You Store Fesoterodine Medical Valley?
Store Fesoterodine Medical Valley at or below 25°C (77°F) in the original packaging to protect from moisture. Keep out of sight and reach of children. Do not use after the expiry date printed on the carton and blister.
Proper storage of your medication is essential to maintain its effectiveness and safety. Fesoterodine Medical Valley extended-release tablets are sensitive to moisture, so it is important to keep them in their original blister packaging until the time of use. Do not transfer the tablets to a different container.
- Temperature: Store at or below 25°C (77°F). Do not refrigerate or freeze.
- Moisture protection: Keep in the original blister packaging. The product is moisture-sensitive.
- Child safety: Keep out of the sight and reach of children at all times.
- Expiry date: Do not use after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of that month.
- Disposal: Do not dispose of medications via wastewater or household waste. Ask your pharmacist how to properly dispose of medicines that are no longer needed. These measures help protect the environment.
What Does Fesoterodine Medical Valley Contain?
The active substance is fesoterodine fumarate. Each 4 mg tablet contains 4 mg fesoterodine fumarate (equivalent to 3.1 mg fesoterodine), and each 8 mg tablet contains 8 mg fesoterodine fumarate (equivalent to 6.2 mg fesoterodine).
Active ingredient
Fesoterodine fumarate is the active pharmaceutical ingredient. It serves as a prodrug that is rapidly converted to the active metabolite 5-hydroxymethyl tolterodine (5-HMT) after absorption. The 4 mg tablet delivers 3.1 mg of fesoterodine base, while the 8 mg tablet delivers 6.2 mg of fesoterodine base.
Inactive ingredients (excipients)
The inactive ingredients in Fesoterodine Medical Valley serve various pharmaceutical purposes including providing structure, controlling drug release, and forming the film coating:
- Tablet core: Fructose, lactose monohydrate, microcrystalline cellulose, hypromellose, glycerol dibehenate, talc
- Film coating: Polyvinyl alcohol, titanium dioxide (E171), macrogol, talc, indigo carmine aluminium lake (E132)
Appearance and pack sizes
The 4 mg tablets are blue, elliptical, biconvex, film-coated tablets approximately 6 mm in diameter, embossed with "F4" on one side and plain on the other. The 8 mg tablets are dark blue with the same shape, embossed with "F8." Fesoterodine Medical Valley is available in blister packs of 10, 14, 28, 30, 56, 84, 98, and 100 extended-release tablets. Not all pack sizes may be marketed in all countries.
Frequently Asked Questions About Fesoterodine Medical Valley
Medical References and Sources
This article is based on current medical research and international guidelines. All claims are supported by scientific evidence from peer-reviewed sources.
- European Medicines Agency (EMA). "Fesoterodine - Summary of Product Characteristics." EMA Product Information European regulatory information for fesoterodine-containing products.
- Chapple CR, et al. (2014). "Randomized, double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of fesoterodine." European Urology. 66(3):479-487. Long-term clinical trial data on fesoterodine safety and efficacy. Evidence level: 1B
- Herschorn S, et al. (2010). "Efficacy and tolerability of fesoterodine in subjects with overactive bladder." BJU International. 106(9):1350-1357. DOI Link Randomized controlled trial of fesoterodine for OAB. Evidence level: 1B
- National Institute for Health and Care Excellence (NICE) (2019). "Urinary incontinence and pelvic organ prolapse in women: management." NICE guideline [NG123]. NICE Guideline UK national guidance on managing urinary incontinence including pharmacotherapy.
- American Urological Association (AUA) / Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) (2019). "Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults." AUA Guidelines American clinical practice guideline for OAB management. Evidence level: 1A
- British National Formulary (BNF). "Fesoterodine fumarate." BNF Drug Monograph UK prescribing reference for fesoterodine, including dosing, interactions, and contraindications.
Evidence grading: This article uses the GRADE framework (Grading of Recommendations Assessment, Development and Evaluation) for evidence-based medicine. Evidence level 1A represents the highest quality of evidence, based on systematic reviews of randomized controlled trials.
iMedic Editorial Standards
Peer Review Process
All medical content is reviewed by at least two licensed specialist physicians before publication.
Fact-Checking
All medical claims are verified against peer-reviewed sources and international guidelines.
Update Frequency
Content is reviewed and updated at least every 12 months or when new research emerges.
Corrections Policy
Any errors are corrected immediately with transparent changelog.
Medical Editorial Board: iMedic has an independent medical editorial board consisting of specialist physicians in urology, pharmacology, internal medicine, and clinical research.